Answers are grounded in this paper and cite their sources.
To assess safety, tolerability, pharmacokinetics, and pharmacodynamics of SAR443820 in first-in-human, Phase 1, randomized, double-blind, placebo-controlled, single-ascending dose (SAD; Part-1a) and multiple-ascending dose (MAD; Part-2) studies in healthy participants. Part-1b was a separate open-label single-dose study for assessing SAR443820 levels in cerebrospinal fluid (CSF).
No takes yet. Share an insight, caveat, or question.
Hincelin-Méry et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: